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OBJECTIVES: To compare the median duration of
treatment persistence for patients with overactive bladder
initiated on oxybutynin XL or tolterodine IR, as well as
the rate of change in treatment between the two regimens.
METHODS: We applied the real-world longitudinal data
(1995–2002) from IMS Mediplus UK to identify all
patients newly diagnosed with overactive bladder and ini-
tiated to therapy with oxybutynin XL or tolterodine IR.
Due to the later entrance of oxybutynin XL, we randomly
selected from the pool of tolterodine IR patients to match
the distribution of study-start dates for the oxybutynin
XL group. Time to ﬁrst modiﬁcation in treatment was the
primary endpoint and assessed using a Cox proportional
hazard model. The rate of change in treatment was the
secondary endpoint and evaluated using a c2 test for sig-
niﬁcant difference in the rate. RESULTS: We identiﬁed
147 patients new to therapy and initiated on oxybutynin
XL. A total of 113 patients were randomly selected from
the tolterodine IR group to match the distribution of
study-start dates from the oxybutynin XL group. Patient
demographics were comparable between both study
groups. The average daily doses were 10.0mg/day for
oxybutynin XL and 4.6mg/day for tolterodine IR. The
median Kaplan-Meier estimates were 56 and 39 days 
for oxybutynin XL and tolterodine IR, respectively (p =
0.03). The rates of change in treatment were 7.5% for
oxybutynin XL compared to 28.3% for tolterodine IR (p
< 0.01). Among the switchers in the tolterodine IR group,
68.8% switched to extended release formulations of
which 45.5% to oxybutynin XL. CONCLUSIONS: Oxy-
butynin XL improved treatment persistence and required
fewer changes when used as ﬁrst line therapy. These
results demonstrate that the therapeutic advantage found
in a randomized clinical trial is reﬂected in the UK real-
world clinical practice setting.
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OBJECTIVE: Few studies have described the treatment
received by patients with SUI symptoms although this is
a condition associated with substantial levels of unmet
need. In the UK, Governmental guidance such as “Good
Practice in Continence Services” (DOH 2000) has identi-
ﬁed geographical variations in continence services as a
problem. Access to specialist services such as pelvic ﬂoor
exercise training (for the treatment of SUI) and the avail-
ability of continence nurses and physiotherapists are
recognised as important. This study aims to identify the
pattern of treatment and service provision for women
with SUI symptoms seeking help in a primary care setting.
METHODS: This cross-sectional, descriptive health out-
comes study targeted all women aged 18 years and over
seeking care at 17 large primary care clinics throughout
the UK. Of 5,447 women approached, 2,400 (44%)
agreed to complete a questionnaire while waiting to be
seen by their care providers. The survey contained self-
report measures of symptom severity, help-seeking, and
care received during the preceding 12 months. Data for
women having SUI symptoms only are reported here.
RESULTS: Fifty-two of the responders reported that they
had SUI symptoms for which they had sought treatment
within primary care in the last year. Sixty-seven percent
of those seeking care were provided reassurance about
their symptoms; 10% were given dietary advice; 5% were
referred to a continence nurse and 12% to physiotherapy;
13% were referred to outpatient clinics, of whom 57%
received surgery. CONCLUSIONS: Most pelvic ﬂoor
exercise training in the UK is provided by continence
nurses or physiotherapists. The other main treatment
option (other than lifestyle advice) is surgical treatment,
which a patient can only access after attending outpa-
tients following GP referral. Only a relatively small per-
centage of patients with SUI symptoms in this study were
accessing these treatment options.
PUK4
TREATMENT OF URINARY INCONTINENCE IN
DAILY PRACTICE DOES NOT COMPLY WITH
THE GUIDELINES
Penning-van Beest FJA1, Sturkenboom MCJM2,
Herings RMC1
1PHARMO Institute, Utrecht, Netherlands; 2Erasmus MC,
Rotterdam, Netherlands
OBJECTIVES: To describe the treatment of urinary
incontinence in relation to the guidelines in non-institu-
tionalized women aged 40 years and older. METHODS:
The source population for this cohort study included all
women aged 40 years and older in the Integrated Primary
Care Information (IPCI) and PHARMO databases.
Patients were included in the urinary incontinence study
cohort if they were newly diagnosed with or treated for
urinary incontinence during the study period. We classi-
ﬁed the type of urinary incontinence and determined the
treatment course during the ﬁrst year. Treatment included
six categories: an absorbent product; a bladder relaxant
